Vesnarinone

Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 ( PDE3 ) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research. In Vitro Vesnarinone (60 and 100 μg/mL; 48 h) inhibits the cell growth in a dose-dependent manner. Vesnarinone (60 μg/mL; 48 h) induces G1 arrest and apoptosis. Vesnarinone (60 μg/mL; 0, 12, 24, and 48 h) treatment increases p21-mRNA expression and decreases p21 protein slightly. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL and 100 μg/mL Incubation Time: 48 hours Result: Observed more than 50% inhibition in cells treated with 100 μg/mL, and reduced 30±40% the production of MTT formazan in cells treated with 60 μg/mL. Apoptosis AnalysisCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL Incubation Time: 48 hours Result: Decreased the tumor cell population in the S phase and increased in the G1 phase. Western Blot AnalysisCell Line: OSC3, OSC4, and OSC5 cells Concentration: 60 μg/mL Incubation Time: 0, 12, 24, and 48 hours Result: Increased the expression of p21-mRNA after 12±24 h vesnarinone treatment. Decreased p21 protein slightly after 24 h treatment in OSC4. In Vivo Vesnarinone (oral gavage; 300 mg/kg; once daily; 6 w) binds covalently to rat liver in vivo. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Lewis rats (200 g)Dosage: 300 mg/kg Administration: Oral gavage; 300 mg/kg; once daily; 6 weeks Result: Observed covalently modified liver proteins.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet